Novo Nordisk A/S: Monlunabant phase 2a trial in obesity successfully completed
Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant, a small molecule oral cannabinoid receptor 1 (CB1) inverse agonist. Monlunabant, formerly INV-202, was part of the acquisition of Inversago Pharmaceuticals Inc.
Novo Nordisk A / S, a healthcare company, is dedicated to the research, development, manufacture and marketing of pharmaceutical products globally. The company is headquartered in Bagsvaerd, ...
On 7 August 2024, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 ...
The firms will collaborate on two lead programs and up to five future targets in other diseases, with NanoVation eligible for up to $600 million in payments from Novo Nordisk.
BAGSVAERD, Denmark I 19, 2024 I Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human ...
Bagsværd, Denmark Saturday, September 21, 2024, 15:00 Hrs [IST] ...
Novo Nordisk's weight-loss drugs ... including one in North Carolina, one in Denmark, and one in Brazil. It's also expanding a number of its existing facilities in Denmark. Meanwhile, over ...
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Novo Nordisk, tje manufacturer behind Ozempic and Wegovy has another weight loss medication in the works — but according to ...
Novo Nordisk's growth slowed and valuation is high, making it not a buy at current prices despite its strong diabetes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback